In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products
- PMID: 20229134
- DOI: 10.1007/s11095-010-0070-5
In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products
Abstract
Purpose: To develop a unique in vitro aqueous fluid-capacity-limited dissolution system for the kinetic assessment of respirable aerosol drug particles from inhaler products.
Methods: Aerosol particles of 5 inhaled corticosteroids (ICSs) from 7 inhaler products were collected in the aerodynamic 2.1-3.3 or 4.7-5.8 mum on the filter membranes using the Andersen cascade impactor. Each filter membrane was then placed onto the donor compartment of the Transwell(R) system, where addition of 0.04ml aqueous fluid initiated aerosol ICS dissolution and permeation across its supporting membrane at 37 degrees C and approximately 100% humidity.
Results: The % profiles of dissolution and permeation were apparent first-order or pseudo-zero-order, reaching varying 1.9-95.0% by 5 h. Their kinetics overall conformed to the ICS aqueous solubility. With increasing aerosol mass, however, the profiles decelerated, attributed to undissolved ICSs left by the limited dissolution fluid capacity. The profiles could be also product-specific, as beclomethasone dipropionate aerosols from QVAR dissolved faster than those from VANCERIL, whereas fluticasone propionate aerosols from two different inhaler products exhibited comparable profiles. The 2.1-3.3 mum aerosols dissolved faster than the 4.7-5.8 mum aerosols.
Conclusions: Aerosol ICS dissolution into the limited aqueous fluid volume differed kinetically due to ICS solubility and aerosol mass, size, formulation and/or generation.
Similar articles
-
In Vivo-Relevant Transwell Dish-Based Dissolution Testing for Orally Inhaled Corticosteroid Products.Pharm Res. 2019 May 9;36(7):95. doi: 10.1007/s11095-019-2635-2. Pharm Res. 2019. PMID: 31073686
-
Evaluation of the Transwell System for Characterization of Dissolution Behavior of Inhalation Drugs: Effects of Membrane and Surfactant.Mol Pharm. 2015 Aug 3;12(8):2618-24. doi: 10.1021/acs.molpharmaceut.5b00221. Epub 2015 Jul 9. Mol Pharm. 2015. PMID: 26091361
-
Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.Int J Pharm. 2014 Apr 25;465(1-2):42-51. doi: 10.1016/j.ijpharm.2014.01.033. Epub 2014 Jan 31. Int J Pharm. 2014. PMID: 24491530
-
Dry powder aerosol delivery systems: current and future research directions.J Aerosol Med. 2006 Spring;19(1):21-7. doi: 10.1089/jam.2006.19.21. J Aerosol Med. 2006. PMID: 16551211 Review.
-
Pediatric in vitro and in silico models of deposition via oral and nasal inhalation.J Aerosol Med Pulm Drug Deliv. 2014 Jun;27(3):149-69. doi: 10.1089/jamp.2013.1075. J Aerosol Med Pulm Drug Deliv. 2014. PMID: 24870701 Review.
Cited by
-
Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products.Mol Pharm. 2019 Mar 4;16(3):1245-1254. doi: 10.1021/acs.molpharmaceut.8b01200. Epub 2019 Feb 15. Mol Pharm. 2019. PMID: 30640475 Free PMC article.
-
Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.AAPS J. 2015 Sep;17(5):1285-304. doi: 10.1208/s12248-015-9787-8. Epub 2015 May 23. AAPS J. 2015. PMID: 26002510 Free PMC article.
-
Preparation, Optimization and In Vitro Characterization of Fluticasoneloaded Mixed Micelles Based on Stearic Acid-g-chitosan as a Pulmonary Delivery System.Recent Adv Drug Deliv Formul. 2024;18(1):61-76. doi: 10.2174/0126673878262764240208054140. Recent Adv Drug Deliv Formul. 2024. PMID: 38362679
-
FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms.AAPS PharmSciTech. 2011 Jun;12(2):782-94. doi: 10.1208/s12249-011-9634-x. Epub 2011 Jun 18. AAPS PharmSciTech. 2011. PMID: 21688063 Free PMC article.
-
Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.Pharmaceutics. 2021 Jul 9;13(7):1051. doi: 10.3390/pharmaceutics13071051. Pharmaceutics. 2021. PMID: 34371741 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical